Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

凯复定 - NMPA Drug Approval Details

Approvals/NMPA/Ceftazidime for Injection

Approved

化学药品

Ceftazidime for Injection

Unknown🇨🇳 National Medical Products Administration

Approval Date: Sep 27, 2023
Approval ID: 8VIYP8JDv5Y
Company: Unknown
Type: 化学药品

Approval Details

Approval Id: 8VIYP8JDv5Y
Approval Number: 国药准字HJ20130653
Generic Name: 注射用头孢他啶
Generic Name En: Ceftazidime for Injection
Trade Name: 凯复定
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 1.0g（按C₂₂H₂₂N₆O₇S₂计）
Reg Date: 2023-09-27
Expired Date: 2028-09-26

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Sep 27, 2023

Approval ID

8VIYP8JDv5Y

Type

化学药品

Back to NMPA Approvals